O Keefe Stevens Advisory Inc. Increases Stake in Amgen Inc. (NASDAQ:AMGN)

O Keefe Stevens Advisory Inc. boosted its stake in Amgen Inc. (NASDAQ:AMGNFree Report) by 0.1% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 48,387 shares of the medical research company’s stock after purchasing an additional 42 shares during the quarter. Amgen comprises about 4.5% of O Keefe Stevens Advisory Inc.’s investment portfolio, making the stock its 4th largest holding. O Keefe Stevens Advisory Inc.’s holdings in Amgen were worth $13,757,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in the stock. BOK Financial Private Wealth Inc. bought a new position in Amgen during the 4th quarter worth approximately $29,000. United Community Bank bought a new position in shares of Amgen during the 4th quarter valued at about $29,000. Providence Capital Advisors LLC bought a new stake in Amgen during the 3rd quarter worth approximately $30,000. Planned Solutions Inc. bought a new stake in Amgen during the 4th quarter worth approximately $30,000. Finally, Delos Wealth Advisors LLC lifted its stake in Amgen by 2,500.0% in the fourth quarter. Delos Wealth Advisors LLC now owns 104 shares of the medical research company’s stock valued at $30,000 after buying an additional 100 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insiders Place Their Bets

In other news, SVP Nancy A. Grygiel sold 2,117 shares of Amgen stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $313.09, for a total value of $662,811.53. Following the completion of the transaction, the senior vice president now owns 9,883 shares in the company, valued at $3,094,268.47. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.69% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. StockNews.com upgraded Amgen from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. Royal Bank of Canada lifted their price objective on shares of Amgen from $328.00 to $332.00 and gave the company an “outperform” rating in a research report on Friday, June 14th. Mizuho boosted their target price on Amgen from $223.00 to $235.00 and gave the stock a “neutral” rating in a report on Thursday, May 9th. Raymond James initiated coverage on shares of Amgen in a research report on Thursday, March 28th. They set a “market perform” rating for the company. Finally, William Blair upgraded Amgen from a “market perform” rating to an “outperform” rating in a research report on Friday, May 3rd. Ten research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat.com, Amgen has a consensus rating of “Moderate Buy” and an average target price of $305.85.

Check Out Our Latest Stock Analysis on AMGN

Amgen Trading Down 0.6 %

Shares of AMGN traded down $1.73 during mid-day trading on Friday, reaching $308.16. 6,933,277 shares of the company were exchanged, compared to its average volume of 2,019,282. The company has a debt-to-equity ratio of 11.96, a quick ratio of 0.98 and a current ratio of 1.42. The business has a 50 day simple moving average of $296.57 and a two-hundred day simple moving average of $290.69. Amgen Inc. has a 52 week low of $218.44 and a 52 week high of $329.72. The stock has a market capitalization of $165.31 billion, a PE ratio of 44.02, a PEG ratio of 2.80 and a beta of 0.60.

Amgen (NASDAQ:AMGNGet Free Report) last issued its quarterly earnings data on Thursday, May 2nd. The medical research company reported $3.96 earnings per share for the quarter, beating the consensus estimate of $3.76 by $0.20. Amgen had a return on equity of 156.21% and a net margin of 12.74%. The business had revenue of $7.45 billion for the quarter, compared to analysts’ expectations of $7.45 billion. During the same period last year, the business earned $3.98 EPS. The business’s revenue was up 22.0% on a year-over-year basis. On average, analysts predict that Amgen Inc. will post 19.47 earnings per share for the current fiscal year.

Amgen Company Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Featured Stories

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.